4.99%
-2.51%
-31.76%
78.88%
-76.97%
-84.10%
-79.61%
AI Spotlight on AMLX
Company Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.It is also developing AMX0035 for other neurodegenerative diseases.
The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Market Data
| Last Price | 3.69 |
| Change Percentage | 4.99% |
| Open | 3.51 |
| Previous Close | 3.51 |
| Market Cap ( Millions) | 316 |
| Volume | 159607 |
| Year High | 19.95 |
| Year Low | 1.57 |
| M A 50 | 4.31 |
| M A 200 | 3.04 |
Financial Ratios
| FCF Yield | -30.27% |
| Dividend Yield | 0.00% |
| ROE | -85.39% |
| Debt / Equity | 1.31% |
| Net Debt / EBIDTA | 27.88% |
| Price To Book | 1.28 |
| Price Earnings Ratio | -0.97 |
| Price To FCF | -3.3 |
| Price To sales | 1.61 |
| EV / EBITDA | -0.99 |
News
- Jan -30 - Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation
- Jan -14 - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation
- Jan -13 - Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
- Jan -12 - Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation
- Jan -10 - Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect
- Jan -10 - Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
- Jan -10 - Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
- Jan -09 - AMLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Amylyx Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
- Jan -08 - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation
- Jan -07 - Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
- Jan -06 - Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect
- Jan -06 - Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer
- Jan -05 - Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation
- Jan -03 - Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
- Dec -31 - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out
- Dec -30 - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out
- Dec -29 - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation
- Dec -24 - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation
- Dec -22 - Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation
- Dec -18 - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Relyvrio (Sodium Phenylbutyrate and Taurursodiol)
Expected Growth : 10.27 %
What the company do ?
Relyvrio is a medication from Amylyx Pharmaceuticals, Inc. that combines Sodium Phenylbutyrate and Taurursodiol to treat amyotrophic lateral sclerosis (ALS).
Why we expect these perspectives ?
Relyvrio's 10.27% growth driven by increasing ALS patient adoption, expanded insurance coverage, and strong marketing efforts. Amylyx's strategic partnerships and investments in clinical trials also contribute to growth. Additionally, the drug's unique mechanism of action and favorable safety profile support its rising demand.
Amylyx Pharmaceuticals, Inc. Products
| Product Range | What is it ? |
|---|---|
| AMX0035 | AMX0035 is an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis (ALS). |
| AMX0035 for other neurodegenerative diseases | AMX0035 is being explored for its potential to treat other neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. |
Amylyx Pharmaceuticals, Inc.'s Porter Forces
Threat Of Substitutes
Amylyx Pharmaceuticals, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for ALS and other neurodegenerative diseases.
Bargaining Power Of Customers
Patients and healthcare providers have limited bargaining power due to the lack of effective treatment options for ALS, giving Amylyx Pharmaceuticals, Inc. an upper hand in pricing and negotiations.
Bargaining Power Of Suppliers
Amylyx Pharmaceuticals, Inc. relies on a few key suppliers for raw materials and manufacturing services, giving them some bargaining power, but the company's strong financial position and diversified supply chain mitigate this risk.
Threat Of New Entrants
The biotechnology industry is highly competitive, and new entrants with innovative treatments for ALS and other neurodegenerative diseases could potentially disrupt Amylyx Pharmaceuticals, Inc.'s market share.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with multiple companies vying for market share and patent protection for their treatments, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 0.97% |
| Debt Cost | 3.95% |
| Equity Weight | 99.03% |
| Equity Cost | 0.53% |
| WACC | 0.57% |
| Leverage | 0.98% |
Amylyx Pharmaceuticals, Inc. : Quality Control
Amylyx Pharmaceuticals, Inc. passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CTMX | CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The … |
| PBYI | Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 … |
| ITOS | Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the … |
| APLT | Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for … |
| HRMY | Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Harmony Biosciences
A-Score
1-Year Total Return ->
🥈
Applied Therapeutics
A-Score
1-Year Total Return ->
🥉
Puma Biotechnology
A-Score
1-Year Total Return ->
4
CytomX Therapeutics
A-Score
1-Year Total Return ->
5
Amylyx Pharmaceuticals
A-Score
1-Year Total Return ->
6
